Safe eradication of large established tumors using neovasculature‐targeted tumor necrosis factor‐based therapies

Safe eradication of large established tumors using neovasculature‐targeted tumor necrosis factor‐based therapies

Abstract Systemic toxicities have severely limited the clinical application of tumor necrosis factor (TNF) as an anticancer agent. Activity‐on‐Target cytokines (AcTakines) are a novel class of immunocytokines with improved therapeutic index. A TNF‐based AcTakine targeted to CD13 enables selective ac...

Full description

Bibliographic Details
Main Authors: Leander Huyghe, Alexander Van Parys, Anje Cauwels, Sandra Van Lint, Stijn De Munter, Jennyfer Bultinck, Lennart Zabeau, Jeroen Hostens, An Goethals, Nele Vanderroost, Annick Verhee, Gilles Uzé, Niko Kley, Frank Peelman, Bart Vandekerckhove, Peter Brouckaert, Jan Tavernier
Format: Article
Language:English
Published: Springer Nature 2020-02-01
Series:EMBO Molecular Medicine
Subjects:
cancer
interferons
neovasculature
targeted therapy
tumor necrosis factor
Online Access:https://doi.org/10.15252/emmm.201911223

Internet

https://doi.org/10.15252/emmm.201911223

Similar Items